On September 24, under the guidance of China Pharmaceutical University, Modern Chinese Mevelopment Research Center, and Chongqing Economic and Information Technology Committee, the 2016 China Pharmaceutical · R&D Innovation Summit and the Release Conference of Top 100 Pharmaceutical Enterprises in R&D Strength, hosted by Medicine Intellectual Elite Club and organized by YAOZH.COM, were grandly held in Chongqing, at which the general ranking and four sub-rankings of "2016 China Drug R&D Comprehensive Strength Ranking" were released. Hansoh Pharma was ranked third in China Chemical Drug R&D Strength Ranking.

The Top 100 companies on the list of comprehensive strength in drug R&D are all outstanding companies with strong new drug R&D strength, quality, innovative spirit and influence in the industry. Today, when China's pharmaceutical companies are changing from sales-driven to R&D-driven, new drug R&D has become the focus and also lifeline of pharmaceutical companies. With the continuous changes in pharmaceutical policies, pharmaceutical companies need to improve their R&D and innovation capabilities on an ongoing basis to remain competitive, so the release of the ranking in drug R&D strength is of great significance.

The final score in the ranking consists of four parts: the score of drug acceptance, the score of drug approval, the score of R&D investment （not applicable to unlisted companies）， and the score of corporate brand. This ensures that the evaluation system is scientific and accurate and the scoring results are objective and fair.

List of the 2016 China Drug R&D Comprehensive Strength Ranking (Partial)